Guidance on the Use of Convalescent Plasma to Treat Immunocompromised Patients With Coronavirus Disease 2019
© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America..
Coronavirus disease 2019 (COVID-19) convalescent plasma (CCP) is a safe and effective treatment for COVID-19 in immunocompromised (IC) patients. IC patients have a higher risk of persistent infection, severe disease, and death from COVID-19. Despite the continued clinical use of CCP to treat IC patients, the optimal dose, frequency/schedule, and duration of CCP treatment has yet to be determined, and related best practices guidelines are lacking. A group of individuals with expertise spanning infectious diseases, virology and transfusion medicine was assembled to render an expert opinion statement pertaining to the use of CCP for IC patients. For optimal effect, CCP should be recently and locally collected to match circulating variant. CCP should be considered for the treatment of IC patients with acute and protracted COVID-19; dosage depends on clinical setting (acute vs protracted COVID-19). CCP containing high-titer severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies, retains activity against circulating SARS-CoV-2 variants, which have otherwise rendered monoclonal antibodies ineffective.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:76 |
|---|---|
| Enthalten in: |
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - 76(2023), 11 vom: 08. Juni, Seite 2018-2024 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bloch, Evan M [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 12.06.2023 Date Revised 24.11.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/cid/ciad066 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM352505974 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM352505974 | ||
| 003 | DE-627 | ||
| 005 | 20231226053858.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/cid/ciad066 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1174.xml |
| 035 | |a (DE-627)NLM352505974 | ||
| 035 | |a (NLM)36740590 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bloch, Evan M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Guidance on the Use of Convalescent Plasma to Treat Immunocompromised Patients With Coronavirus Disease 2019 |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.06.2023 | ||
| 500 | |a Date Revised 24.11.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. | ||
| 520 | |a Coronavirus disease 2019 (COVID-19) convalescent plasma (CCP) is a safe and effective treatment for COVID-19 in immunocompromised (IC) patients. IC patients have a higher risk of persistent infection, severe disease, and death from COVID-19. Despite the continued clinical use of CCP to treat IC patients, the optimal dose, frequency/schedule, and duration of CCP treatment has yet to be determined, and related best practices guidelines are lacking. A group of individuals with expertise spanning infectious diseases, virology and transfusion medicine was assembled to render an expert opinion statement pertaining to the use of CCP for IC patients. For optimal effect, CCP should be recently and locally collected to match circulating variant. CCP should be considered for the treatment of IC patients with acute and protracted COVID-19; dosage depends on clinical setting (acute vs protracted COVID-19). CCP containing high-titer severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies, retains activity against circulating SARS-CoV-2 variants, which have otherwise rendered monoclonal antibodies ineffective | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, U.S. Gov't, Non-P.H.S. | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a antibodies | |
| 650 | 4 | |a immunocompromised host | |
| 650 | 4 | |a passive immunization | |
| 650 | 4 | |a plasma | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 700 | 1 | |a Focosi, Daniele |e verfasserin |4 aut | |
| 700 | 1 | |a Shoham, Shmuel |e verfasserin |4 aut | |
| 700 | 1 | |a Senefeld, Jonathon |e verfasserin |4 aut | |
| 700 | 1 | |a Tobian, Aaron A R |e verfasserin |4 aut | |
| 700 | 1 | |a Baden, Lindsey R |e verfasserin |4 aut | |
| 700 | 1 | |a Tiberghien, Pierre |e verfasserin |4 aut | |
| 700 | 1 | |a Sullivan, David J |e verfasserin |4 aut | |
| 700 | 1 | |a Cohn, Claudia |e verfasserin |4 aut | |
| 700 | 1 | |a Dioverti, Veronica |e verfasserin |4 aut | |
| 700 | 1 | |a Henderson, Jeffrey P |e verfasserin |4 aut | |
| 700 | 1 | |a So-Osman, Cynthia |e verfasserin |4 aut | |
| 700 | 1 | |a Juskewitch, Justin E |e verfasserin |4 aut | |
| 700 | 1 | |a Razonable, Raymund R |e verfasserin |4 aut | |
| 700 | 1 | |a Franchini, Massimo |e verfasserin |4 aut | |
| 700 | 1 | |a Goel, Ruchika |e verfasserin |4 aut | |
| 700 | 1 | |a Grossman, Brenda J |e verfasserin |4 aut | |
| 700 | 1 | |a Casadevall, Arturo |e verfasserin |4 aut | |
| 700 | 1 | |a Joyner, Michael J |e verfasserin |4 aut | |
| 700 | 1 | |a Avery, Robin K |e verfasserin |4 aut | |
| 700 | 1 | |a Pirofski, Liise-Anne |e verfasserin |4 aut | |
| 700 | 1 | |a Gebo, Kelly A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical infectious diseases : an official publication of the Infectious Diseases Society of America |d 1992 |g 76(2023), 11 vom: 08. Juni, Seite 2018-2024 |w (DE-627)NLM012603007 |x 1537-6591 |7 nnns |
| 773 | 1 | 8 | |g volume:76 |g year:2023 |g number:11 |g day:08 |g month:06 |g pages:2018-2024 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/cid/ciad066 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 76 |j 2023 |e 11 |b 08 |c 06 |h 2018-2024 | ||